Blog

Looking for the next big breakthrough in CAR-T, Mike Gilman debuts Obsidian with $49.5M round – Endpoints News


Endpoints News

Looking for the next big breakthrough in CART, Mike Gilman debuts Obsidian with $49.5M round
Endpoints News
Building off some research work he'd done in the lab for years, the crew has been working with what he calls destabilizing domains, mutants which can be encoded in a “synthetic biologic cassette,” packaged in a vector and dispatched to tinker with an
Obsidian launches with $49.5 million to fine tune cellular and gene therapiesChemical & Engineering News


Biogen vet launches cancer drug startup with $50M from GV, othersBoston Business Journal
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy …Business Wire (press release)

all 5 news articles »

2017-12-06 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.